REGN

Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

05/08 09:30 am

Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

05/05 01:00 pm

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

04/30 01:00 pm

Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today

04/29 12:34 pm

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

04/29 07:00 am

Regeneron Strikes Deal With Trump Administration To Cut Drug Prices

04/24 12:08 pm

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

04/23 10:04 pm

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

04/23 03:46 pm

Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight

04/23 01:00 pm

FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat

04/23 11:02 am

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

04/22 05:30 pm

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

04/22 05:30 pm

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

04/21 04:34 am

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

04/16 01:00 pm

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

04/15 01:00 pm

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

04/13 01:00 pm

Neomorph Announces Closing of $100 Million Series B Financing

04/13 09:00 am

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

04/13 08:38 am

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

04/13 01:00 am

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

04/13 01:00 am

Atopic Dermatitis (7MM) Drug Market Forecast and Analysis Report 2023-2033: Opportunities Remain for the Treatment of AD, Novel Systemic Therapies Dominate the Late-stage Pipeline

04/10 04:52 am

Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033

04/10 04:46 am

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

04/07 07:02 am

Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

04/06 01:20 pm

AstraZeneca Strengthens Position In COPD Race With Successful Trials

03/27 08:46 am

Is Regeneron a Multimillionaire-Maker Stock?

03/27 08:30 am

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

03/24 02:00 am

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse

03/24 02:00 am

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

03/17 10:46 pm

Is Eli Lilly's Weight Loss Empire in Trouble?

03/13 06:30 pm

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

03/10 10:59 pm

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

03/10 09:29 pm

Lamzede (Chiesi Farmaceutici) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

03/10 06:50 am

2 Biotech Giants to Buy in 2026

03/05 09:15 am

Skeletal Dysplasia Market - Global Forecast 2026-2032: $5.37 Bn Opportunities Driven by Advancing Diagnostic Precision, Integrated Therapies, Evidence Generation, and Equitable Access

03/05 05:51 am

Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036

02/25 10:00 am

2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years

02/24 08:16 pm

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

02/24 02:47 pm

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

02/13 02:45 pm

Decoding Our DNA: The Human Impact Behind SNP Genotyping’s USD 19.48 Billion Growth by 2034

02/13 11:00 am

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

02/13 09:23 am

CytomX Therapeutics to Present at Upcoming February Conferences

02/04 09:00 am

This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend

02/02 07:33 am

This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business

01/30 07:25 pm

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

01/30 11:56 am

Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR

01/27 11:00 am

Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative

01/21 10:43 am

Regeneron Just Moved From Underperform To Buy - Here's Why

01/07 05:18 pm

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow

12/13 11:01 am

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

12/08 09:00 am